Cellectis Presents Preclinical Data for .HEAL-101 at ESGCT 2026
Cellectis announced positive preclinical data for its in vivo gene-editing candidate .HEAL-101, which targets APOC3 for the treatment of severe hypertriglyceridemia.
Stocks · News reference
U.S. stocks fell Monday as tech slid; Nvidia may invest $10B in Anthropic’s IPO. Oil rose 3%, while gold, silver and copper declined.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Cellectis announced positive preclinical data for its in vivo gene-editing candidate .HEAL-101, which targets APOC3 for the treatment of severe hypertriglyceridemia.
Cantor Fitzgerald has reaffirmed its Overweight rating on The Elmet Group Co.
Corning reported Q3 2026 results that beat analyst expectations with $5.08B in core sales and $0.91 EPS, but shares fell as investors focused on disappointing solar business performance. The solar division saw flat revenue at $436M and a $7M net loss, reversing prior year profitability. Despite strong overall results and positive Q4 guidance, the stock trades at 30.8x forward earnings, prompting caution from investors.
Corning Incorporated announced its third-quarter 2026 financial results, reporting core sales of $5.08 billion and core EPS of $0.91, exceeding previous guidance.
Filed: 2026-10-27 AccNo: 0000024741-26-000273 Size: 952 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Visa is Tuesday’s most material report, with investors looking for continued payments growth after a strong run in the stock. Coca-Cola, HSBC Holdings, Novartis, Boeing and S&P Global report before the open; Seagate